ISSN 1526-632X
25 papers in the library · 1,533 citations · publishing 1955-2026
Neurology June 9, 2026 Emmanuelle A. D. Schindler, Kevin Lenaburg, Robert Wold
To carry out a survey on N,N-dimethyltryptamine (DMT) use in adults with cluster headache.
Neurology April 7, 2025 Emmanuelle A. D. Schindler, Christopher Gottschalk, Deepak Cyril D’souza 2 citations
To examine the relationship of acute psychedelic effects and measures of mental health with headache frequency in clinical trials of psilocybin in migraine and cluster headache.
Neurology March 30, 2025 Julian Ungar-Sargon
This article examines the question of whether living beings possess an innate, unchangeable nature or have the capacity for fundamental transformation a question with profound implications for treating addiction-related physical illness. By integrating diverse perspectives from religious and philosophical traditions, mystical thought, modern neuroscience, genetics, and clinical approaches to...
Neurology February 25, 2025 David Fischer, Brian L Edlow, Holly J Freeman et al. 9 citations
Determining the level of consciousness in patients with brain injury-and more fundamentally, establishing what they can experience-is ethically and clinically impactful. Patient behaviors may unreliably reflect their level of consciousness: a subset of unresponsive patients demonstrate covert consciousness by willfully modulating their brain activity to commands through fMRI or EEG. However,...
Neurology April 9, 2024 Tina Singh, Dipa Patel, Kasey Bishop et al. 1 citation
To uncover the underlying mechanisms between the usage of psilocybin and its impact on the rehabilitation from substance use disorders (SUD).
Neurology September 19, 2018 K. Fox, Jennifer Yih, Omri Raccah et al.
Objective We applied direct cortical stimulation (DCS) to the orbitofrontal cortex (OFC) in neurosurgical patients implanted with intracranial electrodes to probe, with high anatomic precision, the causal link between the OFC and human subjective experience. Methods We administered 272 instances of DCS at 172 OFC sites in 22 patients with intractable focal epilepsy (from 2011 to 2017), none of...
Neurology September 5, 2018 L. Weizman, Lior Dayan, Silviu Brill et al.
Objective To characterize the functional brain changes involved in δ-9-tetrahydrocannabinol (THC) modulation of chronic neuropathic pain. Methods Fifteen patients with chronic radicular neuropathic pain participated in a randomized, double-blind, placebo-controlled trial employing a counterbalanced, within-subjects design. Pain assessments and functional resting state brain scans were performed...
Neurology September 29, 2015 Venus Tang, Wai S Poon, Patrick Kwan
To investigate the effectiveness of mindfulness-based therapy (MT) and social support (SS) in patients with drug-resistant epilepsy. We performed an assessor-blinded randomized control trial. Sixty patients with drug-resistant epilepsy were randomly allocated to MT or SS (30 per group). Each group received 4 biweekly intervention sessions. The primary outcome was the change in the total score...
Neurology April 6, 2015 Thananan Thammongkolchai, Pichet Termsarasab, Ayham Alkhachroum et al. 43 citations
Objective: To report the first case of myoclonus as neurologic presentation of 5-MeO-DALT abuse Background: 5-Meo-DALT (N,N-diallyl-5-methoxytryptamine) is a relatively new hallucinogen, initially sold online in 2004. It is a psychedelic compound from the tryptamine family which affects monoamine neurotransmitters including dopamine and serotonin. It is a psychostimulant with strong visual...
Neurology April 8, 2014 Y. Umemura, T. Andrew, V. Jacobs et al.
OBJECTIVE: To describe a fatal outcome due to ingestion of a new designer drug, 25I-NBOMe. BACKGROUND: Abuse of synthetic drugs has been on the rise, and many are sold over-the-counter as bath salts and fertilizer. Identification of the exposure to such chemicals is often difficult due to the paucity of available specific laboratory assays. 25I-NBOMe stands for...
Neurology September 3, 2013
The increasing prevalence of allergic airway diseases in industrialized countries has been associated with high hygienic standards and reduced microbial exposure. Probiotic lactic acid bacteria, such as certain Lactobacillus strains, were shown to have potentially beneficial immunomodulatory properties. Therefore, we determined the effect of intranasal administration of L. rhamnosus GG (LGG)...
Neurology February 12, 2013 R. Wells, Gloria Y Yeh, C. Kerr et al.
OBJECTIVE: Our objective was to determine whether Mindfulness Based Stress Reduction (MBSR) would improve functional connectivity of the DMN and reduce hippocampal atrophy among adults with Mild Cognitive Impairment (MCI).
Neurology July 4, 2011 Una D. Mccann, Francis P. Sgambati, Alan R. Schwartz et al. 1 citation
Background: Methylenedioxymethamphetamine (MDMA, "ecstasy") is a popular recreational drug of abuse and a selective brain serotonin neurotoxin.Functional consequences of MDMA neurotoxicity have defied ready characterization.Obstructive sleep apnea (OSA) is a common form of sleep-disordered breathing in which brain serotonin dysfunction may play a role.The present study sought to determine...
Neurology January 13, 2011 Jeffrey R. Petrella, Forrest Sheldon, Steven E. Prince et al. 291 citations
OBJECTIVE: Dysfunction of the default mode network (DMN) has been identified in prior cross-sectional fMRI studies of Alzheimer disease (AD) and mild cognitive impairment (MCI); however, no studies have examined its utility in predicting future cognitive decline. METHODS: fMRI scans during a face-name memory task were acquired from a cohort of 68 subjects (25 normal control, 31 MCI, and 12 AD)....
Neurology September 1, 2010
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial.
Neurology March 5, 2007 Kevin R. Nelson, Michelle Mattingly, Frederick A. Schmitt 60 citations
In a study of more than 13,000 Europeans, 5.8% reported the out-of-body experience (OBE) form of autoscopy.1 Occurring in diverse clinical settings, OBE is also typical of near death experience (NDE). NDE are responses to life-threatening crisis characterized by a combination of dissociation from the physical body, euphoria, and transcendental or mystical elements. Persons with NDE may have an...
Neurology June 26, 2006 R. Andrew Sewell, John H. Halpern, Harrison G. Pope 259 citations
The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition. Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks; 25 of 48 psilocybin users and 7 of 8 LSD users reported cluster period termination; 18 of 19 psilocybin users and 4 of 5 LSD users reported remission period extension. Research on...
Neurology April 10, 2006 Kevin R. Nelson, Michelle Mattingly, Sherman A. Lee et al. 120 citations
The neurophysiologic basis of near death experience (NDE) is unknown. Clinical observations suggest that REM state intrusion contributes to NDE. Support for the hypothesis follows five lines of evidence: REM intrusion during wakefulness is a frequent normal occurrence, REM intrusion underlies other clinical conditions, NDE elements can be explained by REM intrusion, cardiorespiratory afferents...
Neurology March 13, 2006 Konstantine K. Zakzanis, Zachariah Campbell 54 citations
The authors further investigated the functional consequences of continued neurotoxicity of (+/-)3,4-methylenedioxymethamphetamine (MDMA) use. Fifteen participants who were previously given a brief neuropsychological battery were tested for a third time 2 years after baseline. At 2 years, seven participants were still using MDMA, whereas eight participants had become abstinent from MDMA since...
Neurology April 10, 2001 Konstantine K. Zakzanis, Donald A. Young 122 citations
To examine the neurotoxic potential of continued MDMA ("Ecstasy") use in humans and its functional consequences over the course of 1 year, 15 MDMA users participated in a longitudinal study in which they completed a brief neuropsychological test battery composed mainly of retrospective and prospective memory tasks. Subjects were abstinent for 2 weeks on initial and 1-year testing. Continued use...
Neurology July 25, 2000 Stephen J. Kish, Yoshiaki Furukawa, Lee-Cyn Ang et al. 119 citations
The authors found that striatal levels of serotonin and those of its metabolite 5-hydroxyindoleacetic acid were severely depleted by 50 to 80% in brain of a chronic user of methylenedioxymethamphetamine (MDMA) whereas concentrations of dopamine were within the normal control range. Our data suggest that MDMA exposure in the human can cause decreased tissue stores of serotonin and therefore some...
Neurology April 12, 1999 Maurice Ohayon, J Zulley, C Guilleminault et al.
Previous epidemiologic data on sleep paralysis (SP) came from small specific samples. The true prevalence and associated factors of SP in the general population remain unknown. A representative sample of the noninstitutionalized general population of Germany and Italy age > or =15 years (n = 8,085) was surveyed by telephone using the Sleep-EVAL questionnaire and the Sleep Questionnaire of...
Neurology December 1, 1998 Karen I. Bolla, Una D. Mccann, George A. Ricaurte 376 citations
Abstinent MDMA users have impairment in verbal and visual memory. The extent of memory impairment correlates with the degree of MDMA exposure and the reduction in brain 5-HT, as indexed by CSF 5-HIAA.
Neurology September 1, 1964 Lawrence C. McHenry 35 citations
Abstract In recent years, specific cortical networks have been proposed to be crucial for sustaining consciousness, including the posterior hot zone and frontoparietal resting state networks (RSN). Here, we computationally evaluate the relative contributions of three RSNs – the default mode network (DMN), the salience network (SAL), and the central executive network (CEN) – to consciousness and...
Neurology May 1, 1955 Howard D. Fabing 41 citations
Background: Patients with ALS commonly exhibit pseudobulbar affect. Methods: The authors conducted a multicenter, randomized, double-blind, controlled, parallel, three-arm study to test a defined combination of dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) (AVP-923) for the treatment of pseudobulbar affect in ALS. Q inhibits the rapid first-pass metabolism of DM. The effects of...